H2K2 / XTL Biopharmaceuticals Ltd. - Depositary Receipt (Common Stock) - Ai+ Enhanced Message Board

XTL Biopharmaceuticals Ltd. - Depositary Receipt (Common Stock)
DE ˙ DB
€ 1.02 ↑0.06 (5.70%)
2025-09-05
BAHAGING PRESYO
Bagikan Pemikiran Anda atau Ajukan Pertanyaan
Bagikan pemikiran Anda. Sertakan tautan dan pemformatan dengan Markdown .
Menggunakan Standar
Other Listings
US:XTLB US$ 1.12
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista

© 2015-2025 Fintel Ventures LLC. All rights reserved. Fintel® is a registered trademark.

This website is provided “as is” without any representations or warranties, express or implied. Fintel makes no representations or warranties in relation to this website or the information and materials provided on this website. Nothing on this website constitutes, or is meant to constitute, advice of any kind. If you require advice in relation to any financial matter you should consult an appropriate professional.

About Fintel
Top Investors
Features
Explore
Help Center